Dr. Cordova R. is a researcher at the German Cancer Research Center (DKFZ) , focusing on nutritional epidemiology and cancer risk factors with a particular interest in the interplay between cardiometabolic diseases , body weight dynamics , and chronic disease outcomes . Their work spans large-scale multinational cohort studies including the European Prospective Investigation into Cancer and Nutrition (EPIC) and UK Biobank . Research interests include: Role of ultra-processed foods in weight gain and obesity Impact of advanced glycation endproducts (AGEs) on cancer risk Genetic and environmental predictors of adiposity gain Association between socioeconomic position and multimorbidity Dietary patterns and CRC molecular pathways Recent publications analyze: Dicarbonyl compounds and weight regulation Stress-induced glucocorticoids and inflammation PLAG1 fusions in CNS tumors Labs/Tasks: EPIC cohort analysis Physical Activity, Nutrition, Alcohol, Cessation of smoking (PANACEA) study International cancer epidemiology collaborations
Giorgio Stassi serves as a Professor in the Department of Surgical and Oncological Disciplines at the School of Medicine and Surgery , University of Palermo . His research focuses on cancer stem cells (CSCs) across colorectal, breast, and thyroid malignancies, with emphasis on microenvironment interactions and therapy resistance mechanisms. Office hours are held weekly at the Laboratory of Cellular and Molecular Pathophysiology in Palermo. His research interests include: Precision Medicine applications in CSC-targeted therapies Immunological profiling of tumor microenvironments Epigenetic and metabolic drivers of chemoresistance Bioinformatic analysis of CSC phenotypes Drug repurposing for CSC eradication Recent publications demonstrate a clear trend toward computational oncology and immunomicroenvironment engineering , with notable work on tumor-on-chip systems, NGS-based prognostics, and macrophage-CSC crosstalk. Key journals include Magazine article and Review essay formats addressing clinical translation of laboratory findings. No scientific awards were documented in the provided materials. His supervisory activities include thesis guidance ("Tesi curate") and Erasmus program coordination, though specific students and projects aren't listed. Research is conducted primarily at the Laboratory of Cellular and Molecular Pathophysiology , with institutional support from the ATeN Center and ASCENT Advanced Studies Centre.
Prof. Dr. Daniel Rückert is the Alexander von Humboldt Professor for Artificial Intelligence at the Technical University of Munich , where he leads the Lab for AI in Medicine . His work bridges computer science, engineering, and medicine to develop AI and machine learning techniques for biomedical data analysis, with a focus on clinical translation. Research Pillars: Biomedical Imaging, Trustworthy AI, Medical Image Computing Clinical Applications: Dementia, Cardiovascular Disease, Cancer, Traumatic Brain Injury Research Focus : Develops AI methodologies for medical imaging workflows (image reconstruction, registration, segmentation) and clinical translation. Key areas include: AI for early disease detection and diagnosis Personalized therapies using multimodal data Privacy-preserving AI systems Cardiac/Neuroimaging applications Scientific Awards : ERC Synergy Grant (2013) & Advanced Grant (2020) Fellowships: British Computer Society (2010), MICCAI (2014), Royal Academy of Engineering (2015), IEEE (2015), Academy of Medical Sciences (2019), IAMBE (2020) Alexander von Humboldt Professorship (2020) Research Projects : Collaborations with Cornell University and University of Oxford on topics like: Hyperspectral neuronavigation for brain tumor surgery Super-resolution MRI techniques Longitudinal aging pattern analysis Medical report generation from clinical conversations
Katherine Janeway, MD, MMSc is an Associate Professor of Pediatrics at Harvard Medical School and serves as Senior Physician at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. She also directs Clinical Genomics at Dana-Farber Cancer Institute. With extensive training including medical school at Harvard, residency in Pediatrics at Boston Combined Residency Program, and fellowship in Pediatric Hematology-Oncology at Boston Children's Hospital and Dana-Farber Cancer Institute, Dr. Janeway has established herself as a leading expert in pediatric bone tumors and cancer genomics. Senior Physician, Dana-Farber/Boston Children's Cancer and Blood Disorders Center Director of Clinical Genomics, Dana-Farber Cancer Institute Associate Professor of Pediatrics, Harvard Medical School Dr. Janeway's research focuses on pediatric sarcomas, particularly Ewing sarcoma and osteosarcoma. Her work spans the spectrum from basic molecular characterization to clinical trial design and implementation. She has made significant contributions to understanding the genomic landscape of pediatric solid tumors, developing precision medicine approaches, and addressing health disparities in pediatric cancer outcomes. Her research integrates genomics, clinical data, and patient-reported outcomes to improve treatment strategies and survival for children with cancer. Analysis of Dr. Janeway's recent publications reveals a strong emphasis on precision oncology in pediatric cancers, with particular focus on Ewing sarcoma and osteosarcoma. Her work spans molecular characterization, clinical trial design, and implementation of genomic-guided therapies. The publications demonstrate growing integration of patient-reported outcomes, health equity considerations, and data-sharing initiatives in pediatric cancer research. Her leadership in Children's Oncology Group studies highlights her role in shaping the future of pediatric cancer treatment through collaborative, evidence-based approaches. Dr. Janeway has served as principal or co-investigator on numerous clinical trials through the Children's Oncology Group, particularly in the Bone Tumor Committee. Her research has been supported by grants from the National Cancer Institute and other major funding organizations focused on advancing pediatric cancer care through genomic medicine and innovative clinical trial designs. As Director of Clinical Genomics at Dana-Farber Cancer Institute, Dr. Janeway leads initiatives to integrate genomic medicine into clinical care for pediatric cancer patients. She is actively involved in the Pediatric MATCH trial and other precision medicine initiatives that match molecular alterations with targeted therapies for children with cancer.
Muhammad Rai is an Assistant Professor at Khalifa University , affiliated with the College of Medicine and Health Sciences in the Department of Biological Sciences . Previously, he served as a research faculty member at Washington University School of Medicine , USA. Dr. Rai earned his PhD in Biochemistry from the Free University of Berlin , Germany, and holds a Master of Science in Cellular and Molecular Biology from Washington University School of Medicine. PhD - Freie Universität Berlin, Germany MSc - Washington University School of Medicine, St. Louis, USA MS - University of Veterinary & Animal Sciences, Lahore, Pakistan Dr. Rai’s research focuses on: Understanding early molecular mechanisms in post-traumatic osteoarthritis Developing nanoparticle-RNAi therapies targeting periostin Investigating genetic heterogeneity in cartilage repair Proteomic and transcriptomic profiling of joint tissues Linking obesity to osteoarthritis via gene expression Elucidating heritability of regenerative capacity His publications span biochemistry, genetics, orthopedics, and nanomedicine , with a focus on post-traumatic osteoarthritis , RNA interference , and mouse models . Key trends include identifying preclinical biomarkers and inflammatory pathway modulation. Awards: K99/R00 Pathway to Independence Award, T32 Postdoctoral Fellowship, multiple ORS and OARSI recognitions Students: Supervising 3 PhD candidates and 2 SRP students Labs: Leads research on musculoskeletal repair at the Center for Biotechnology Research
Annette Molinaro is a Research Professor at the University of California San Francisco (UCSF) School of Medicine, serving as Director of Biomedical Statistics and Informatics for the Department of Neurological Surgery. She leads biostatistical cores for the Brain SPORE and Program Project, specializing in machine learning and statistical modeling for cancer research, including imaging, genetics, and immunology applications. Education: BS in Statistics from Florida State University, MA/PhD in Biostatistics from UC Berkeley, and National Cancer Institute fellowship in Cancer Prevention. Her research focuses on developing AI-driven risk prediction models for gliomas, analyzing immune profiling, DNA methylation, and high-dimensional data. She has contributed to over 150 publications and created open-source software for genomic data analysis. Recent work highlights applications in glioma subtyping, drug delivery optimization, and equity-focused AI tools. Her grants include NIH funding as co-PI for brain tumor SPORE projects and PI roles in genomic risk prediction studies. Scientific Awards: Evelyn Fix Prize, Chin Long Chiang Biostatistics Student of the Year, Teacher of the Year at Yale, Diane D. Ralston Clinical Neuroscience Teaching Award, and election to the International Statistical Institute. Molinaro co-leads the 'Series on Biostatistics for the Practicing Clinician' in Neuro-Oncology Practice and contributes to diversity initiatives in neuro-oncology, emphasizing equitable research practices.
Tim Triche, Jr., Ph.D., is an Associate Professor at the Van Andel Institute in the Department of Epigenetics . He earned his A.B. in chemistry from Cornell University , followed by an M.S. in biostatistics and a Ph.D. in statistical genetics from the University of Southern California . Before joining Van Andel in 2017, he was a postdoctoral fellow at USC's Norris Comprehensive Cancer Center focusing on cellular senescence in blood disorders. As a key member of The Cancer Genome Atlas Research Network since 2011 with over a dozen high-impact publications in Nature , Cell , and NEJM , Dr. Triche specializes in epigenetics , biostatistics , and computational biology . His lab develops innovative approaches for pediatric AML research, integrating next-generation sequencing with clinical trial design to improve patient outcomes. His work emphasizes statistical learning for patient stratification, molecular profiling of hematological cancers, and interpretable machine learning in biomedical contexts. He leads the Bioinformatics and Biostatistics Core as faculty advisor and maintains active collaborations across institutions. 2025 Nature Cancer study on developmental heterogeneity in cancer susceptibility 2024 NAR methods paper on BISCUIT multi-omics tools 2023 PLOS One validation of MAX regulation in pituitary adenomas 2022 Nature Metabolism obesity subtyping analysis Scientific contributions include: Chan Zuckerberg Initiative grant (2022) for biomedical computing NCI SPORE grant (2021) as co-recipient Key role in Pediatric AML molecular mapping (2017)
Ramin Karim is a Professor and Head of Subject in the Department of Civil, Environmental and Natural Resources Engineering at Luleå University of Technology. His research focuses on operation and maintenance technology, with expertise in railway systems, industrial cybersecurity, structural health monitoring, and the application of advanced analytics in asset management. He leads the Operation, Maintenance and Acoustics division, emphasizing interdisciplinary approaches to solving complex engineering challenges. Key research areas include predictive maintenance strategies for railway infrastructure, cybersecurity frameworks for Industry 5.0, and the integration of metaverse technologies in industrial contexts. His work often involves data-driven methodologies such as point-cloud processing, game theory for cyber threat modeling, and digital twin concepts. Recent publications highlight his contributions to railway maintenance policy optimization, health monitoring of ground support systems in mining, and cybersecurity challenges in industrial systems. He has co-authored over 50 peer-reviewed articles, many appearing in high-impact journals like International Journal of Systems Assurance Engineering and Management and Frontiers in Virtual Reality . Ramin Karim’s research also explores emerging technologies like federated learning for digital twins, blockchain applications in railways, and human-centric predictive health management systems. His work aligns with initiatives such as the Reality Lab Digital Railway, aimed at advancing sustainable and digitally enabled transportation solutions.
Martin Stockler is Professor of Oncology and Clinical Epidemiology at The University of Sydney, with dual clinical roles as a consultant medical oncologist at Concord Repatriation General Hospital and Chris O’Brien Lifehouse RPA. He serves as Oncology Director at the NHMRC Clinical Trials Centre and has led major international clinical trials in genitourinary, gynaecologic, and thoracic cancers. His research integrates clinical epidemiology with innovative trial designs to improve patient outcomes. MBBS (Hons), University of Sydney MSc in Clinical Epidemiology, University of Toronto FRACP (Fellow of the Royal Australasian College of Physicians) His research focuses on clinical trials to enhance quality of life , survival , and doctor-patient communication in cancer care. Key areas include prognostication in advanced cancer, genitourinary oncology , and evidence-based medicine . Recent work emphasizes PSMA PET imaging , lipid biomarkers , and theranostic approaches like [177Lu]Lu-PSMA-617 therapy. Publications span topics in phase III trials (ENZAMET, OUTBACK), biomarker validation (PCPro, PSMA PET), and patient-centered outcomes . Notable contributions include systematic reviews on prognostic discussions and patient-reported outcome measures in ovarian, testicular, and gastric cancers. He has authored book chapters on cancer communication and clinical decision-making .
Dr. Shaun Markovic is a Lecturer in Psychology at the School of Arts and Humanities, Edith Cowan University. His research focuses on healthy ageing strategies, cognitive health preservation, and the impacts of concussion/TBI across populations. He holds a PhD from Murdoch University (2023) and prior degrees from the University of Western Australia. Education: Doctor of Philosophy, Murdoch University, 2023 Bachelor of Science with First Class Honours in Psychology, University of Western Australia, 2013 Bachelor of Science (Psychology), University of Western Australia, 2012 Research interests include: Exercise interventions for cognitive health Early detection of dementia Post-concussion recovery mechanisms Cardiorespiratory fitness biomarkers His recent work explores the interplay between lifestyle factors (e.g., sleep, diet) and neurocognitive outcomes in aging populations. Key themes include: Alzheimer’s disease risk mitigation via physical activity Genetic (ApoE) influences on cognitive decline Healthcare utilization patterns post-mTBI Current supervision includes a PhD candidate exploring adherence to cognitive training in older adults. No awards explicitly noted in the provided texts.
Emily J. Gilmore, MD is a Professor of Neurology and Neurosurgery at Yale School of Medicine , where she serves as Clinical Chief of the Division of Neurocritical Care and Emergency Neurology, Director of the Neurosciences Intensive Care Unit, and Co-Director of Neurotrauma. She co-leads the Critical Care EEG Program and holds appointments in both Neurology and Neurosurgery. Board-certified in Clinical Neurophysiology (AB of Clinical Neurophysiology, 2015) Director of Neuro-ICU and Neuromonitoring programs Principal Investigator for national neurotrauma trials Her research focuses on physiologic biomarkers from multimodal brain monitoring to personalize care for acute brain injury patients. Key areas include: Traumatic Brain Injury (TBI) Status Epilepticus management Subarachnoid Hemorrhage Stroke and Cardiac Arrest outcomes Recent studies highlighted her work on: Genetic risk factors (APOE ε4, polygenic profiling) for hemorrhage Quantitative EEG and neuroimaging for epilepsy prediction Pupillometry as a prognostic tool in stroke Automated CT analysis for post-traumatic epilepsy risk Scientific recognition includes: A.B. Baker Teacher Recognition Award (2020) Fellow of the American Clinical Neurophysiology Society (2019) and Neurocritical Care Society (2020) Board Member, American Board of Clinical Neurophysiology (2022) As a clinical investigator, she leads the BOOST3 Phase 3 trial for TBI and contributes to ASPIRE and BEACH stroke studies. Her lab collaborates with teams at MGH and UTSW on biomarker research.
Dr. James Laird is an Assistant Professor of Therapeutic Radiology at Yale School of Medicine. He sees patients at Smilow Cancer Hospital in Waterford and is affiliated with Yale Cancer Center and Yale Medicine. His clinical practice focuses on treating thoracic, head and neck, gastrointestinal, skin, and gynecologic malignancies using advanced radiotherapy techniques. Dr. Laird received his BA from Columbia University in 2013, followed by his MD from New York University School of Medicine in 2018, where he was inducted into the Alpha Omega Alpha honor society and named the highest performing student in the preclinical curriculum. He completed his internship at Lenox Hill Hospital in 2019 and his residency in radiation oncology at Yale New Haven Hospital in 2023, serving as Chief Resident for the 2022-2023 academic year. Dr. Laird's research primarily focuses on the role of local treatments in oligometastatic cancer, aiming to improve patient outcomes through innovative radiation approaches. His work spans multiple cancer types including lung cancer, head and neck cancers, breast cancer, and gynecologic malignancies. He has developed expertise in radiation pneumonitis, radiation recall phenomena, and the integration of novel agents like PARP inhibitors with radiation therapy. His research often addresses both clinical applications and healthcare policy aspects of radiation oncology. Analysis of Dr. Laird's publication history reveals a strong focus on gynecologic cancers (particularly ovarian, endometrial, cervical, vaginal, and vulvar cancers), head and neck malignancies, and small cell lung cancer. His work bridges basic science with clinical applications, particularly in the areas of radiation toxicity, novel combination therapies, and healthcare economics in radiation oncology. A notable trend in his research is the exploration of molecular imaging techniques to monitor therapeutic efficacy, as well as investigations into the relationship between radiation therapy and systemic treatments. Inducted into Alpha Omega Alpha honor society during medical school Named highest performing student in preclinical curriculum at NYU School of Medicine While specific details about his advising activities are not provided in the source material, Dr. Laird served as Chief Resident for the 2022-2023 academic year at Yale, indicating leadership in resident education. His research collaborations include frequent co-authors such as Melissa Rasar Young, MD, PhD; James B. Yu, MD; Jonathan Leventhal, MD; Shari Damast, MD; and Yi An, MD. These collaborations span multiple aspects of radiation oncology including gynecologic cancers, head and neck cancers, and healthcare policy. Dr. Laird is part of the Therapeutic Radiology department at Yale School of Medicine, which includes the Smilow Cancer Hospital, Yale Gamma Knife Center, and multiple satellite cancer care centers. His work contributes to the department's comprehensive approach to cancer treatment, combining clinical care with research innovation.
Stuart S. Martin, PhD is a Professor and the Drs. Angela and Harry Brodie Professor of Translational Cancer Research at the University of Maryland School of Medicine. He serves as Interim Chair of the Department of Pharmacology and Physiology and Deputy Director of the Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). Additionally, Dr. Martin co-leads the Hormone-Related Cancers (HRC) program, which comprises 45 investigator labs focused on breast, prostate, and ovarian cancers. Dr. Martin's educational background includes: Ph.D. in Biomedical Sciences from the University of California-San Diego, with a focus on insulin-stimulated rearrangement of the actin cytoskeleton Postdoctoral training in Dr. Phil Leder's lab at Harvard Medical School, studying how cell shape and the actin cytoskeleton influence cell survival Joined the University of Maryland School of Medicine in 2004 as an Assistant Professor Dr. Martin's research primarily focuses on cancer metastasis , particularly in breast cancer. His laboratory investigates how epithelial cells undergo apoptosis following detachment from the extracellular matrix and how metastatic breast tumor cells evade this cell death. A significant portion of his work centers on microtentacles - tubulin-based protrusions that form in detached tumor cells and promote metastasis by enhancing cell reattachment. His research integrates functional genomics , proteomics , and in vivo tumor imaging to identify metastasis-enhancing genes and understand their mechanisms. His most recent publications (2019-2021) demonstrate a continued focus on microtentacles and their role in cancer metastasis, with increasing incorporation of bioengineering approaches like microfluidics and novel cell capture technologies. His work bridges basic cell biology with translational applications, particularly in circulating tumor cell analysis and cancer diagnostics. A notable trend is the expansion from breast cancer to other cancer types like glioblastoma, suggesting broader applicability of his findings. Dr. Martin has received significant recognition for his work, including: The Drs. Angela and Harry Brodie Endowed Professorship in Translational Cancer Research (2020) As co-leader of the Hormone-Related Cancers program, Dr. Martin oversees a collaborative network of 45 investigator labs. His laboratory has established innovative methodologies for studying circulating tumor cells and metastasis, including the development of the TetherChip technology for microtentacle fixation and analysis. His work has implications for identifying patients at higher risk of metastasis and developing interventions to prevent cancer spread. The Martin Laboratory, located at 655 W. Baltimore Street in the Bressler Research Building, is actively engaged in research on cancer cell mechanics, metastasis, and novel diagnostic approaches. The lab maintains a strong collaborative presence within the University of Maryland Greenebaum Comprehensive Cancer Center and partners with researchers across multiple disciplines including bioengineering, oncology, and cell biology.
Dr. Jianyang HU serves as a Research Assistant Professor in the Department of Biochemistry at the School of Medicine, Southern University of Science and Technology (SUSTech). He joined SUSTech in July 2021 after completing postdoctoral training at City University of Hong Kong, where he earned his PhD in Biomedical Sciences in 2020. His educational background includes a Master's in Pharmacology from Jinan University (2012-2015) and a Bachelor's in Pharmacy from Guangzhou University of Chinese Medicine (2008-2012). His research focuses on tumor cell senescence regulation , cancer metastasis mechanisms , and cell-cell communications in the tumor microenvironment , particularly through exosome-mediated pathways. His work primarily investigates triple-negative breast cancer using models like circulating tumor cells. Dr. HU's publication record shows strong engagement in cancer biology with 13 papers in high-impact journals including Nature Communications (IF:17.694) and British Journal of Cancer (IF:9.08), accumulating over 480 citations and an H-index of 10. His research spans molecular oncology, drug discovery, and cancer pharmacology with emphasis on transcriptional regulation, stemness, and metastasis. National Natural Science Foundation Youth Project Shenzhen Science and Technology Innovation Commission Youth Project China Postdoctoral Program Guangdong Overseas Postdoctoral Talents Support Project He has applied for 3 Chinese patents and 2 US patents related to cancer therapeutics. Currently working in Prof. Xin Hong's research group at SUSTech, Dr. HU's work aims to identify novel drug targets for tumor treatment through mechanistic studies of cellular senescence and metastasis.
Nancy Du is an Associate Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College specializing in cancer metastasis mechanisms. She holds the Mildred L. and John F. Rasweiler Research Scholar in Cancer Research title and maintains active collaborations with Northwell Health through professional services. B.S., National Tsing Hua University (Taiwan) Ph.D., State University of New York at Stony Brook Her research focuses on: Bcl-xL's non-apoptotic role in metastasis RHAMM isoform B in pancreatic cancer progression Carbon monoxide-based anti-metastatic therapies MicroRNA regulation of tumor suppressors Epigenetic mechanisms in oncogenesis Tumor microenvironment interactions Publications (2024-2019) highlight advancements in: Murine cancer models Epigenetic metastatic drivers Nanotherapy approaches T cell infiltration in tumors miRNA-dysregulated pathways Bcl-xL mutation analysis Scientific honors include: Mildred L. and John F. Rasweiler Research Scholar in Cancer Research Current grants (2024-2027): DoD: Bcl-xL in breast cancer metastasis Manhasset Women's Coalition: CO-based breast cancer prevention NCI: RHAMM B in pancreatic cancer metastasis
